(SRT) Sartorius VZO O.N. - Ratings and Ratios
Exchange: XETRA • Country: Germany • Currency: EUR • Type: Common Stock • ISIN: DE0007165607
SRT: Bioreactors, Fermenters, Filters, Pipettes, Balances, Software
Sartorius AG, traded as SRT on the XETRA exchange, is a German-based company with a market capitalization of 14,507.36 million EUR. Established in 1870 and headquartered in Göttingen, Germany, Sartorius operates in the Health Care Equipment industry. The company specializes in providing bioprocess solutions and laboratory products, serving sectors such as life science research, biopharmaceutical manufacturing, and pharmaceutical quality control.
Their product portfolio includes a variety of bioreactors, ranging from multi-parallel to stainless steel models, complemented by software applications for efficient bioprocessing. Additionally, they offer cell culture media, microfluidic components, and advanced filtration systems, which are critical for both research and production environments.
Sartorius also provides analytical instruments, including live-cell analysis systems and chromatography tools, along with process automation platforms that integrate data analytics. These solutions cater to the increasing demand for data-driven decision-making in the biotech and pharmaceutical industries.
Moreover, the company offers a range of services such as bioprocess consulting, biologics testing, and validation support, which are essential for optimizing manufacturing processes and ensuring regulatory compliance. Their financials indicate a trailing P/E of 167.93 and a forward P/E of 39.53, with a P/S ratio of 4.36, reflecting their growth prospects and market valuation.
With a strong foundation in the life sciences sector, Sartorius AG is well-positioned to support advancements in biopharma and applied industries, making it a key player in the global healthcare equipment market.
Additional Sources for SRT Stock
SRT Stock Overview
| Market Cap in USD | 13,895m |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| GiC Sub-Industry | Health Care Equipment |
| IPO / Inception |
SRT Stock Ratings
| Growth Rating | -40.5 |
| Fundamental | 12.3 |
| Dividend Rating | 24.0 |
| Rel. Strength | -29.9 |
| Analysts | - |
| Fair Price Momentum | 149.66 EUR |
| Fair Price DCF | 341.65 EUR |
SRT Dividends
| Dividend Yield 12m | 0.40% |
| Yield on Cost 5y | 0.31% |
| Annual Growth 5y | -7.01% |
| Payout Consistency | 94.0% |
SRT Growth Ratios
| Growth Correlation 3m | -90.7% |
| Growth Correlation 12m | -43.6% |
| Growth Correlation 5y | -67% |
| CAGR 5y | -5.87% |
| CAGR/Max DD 5y | -0.07 |
| Sharpe Ratio 12m | -0.64 |
| Alpha | -30.90 |
| Beta | 0.688 |
| Volatility | 56.05% |
| Current Volume | 3.2k |
| Average Volume 20d | 4k |
As of April 19, 2025, the stock is trading at EUR 172.60 with a total of 3,215 shares traded.
Over the past week, the price has changed by +16.15%, over one month by -10.47%, over three months by -6.41% and over the past year by -30.25%.
Neither. Based on ValueRay Fundamental Analyses, Sartorius VZO O.N. is currently (April 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 12.30 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of SRT as of April 2025 is 149.66. This means that SRT is currently overvalued and has a potential downside of -13.29%.
Sartorius VZO O.N. has no consensus analysts rating.
According to ValueRays Forecast Model, SRT Sartorius VZO O.N. will be worth about 163.2 in April 2026. The stock is currently trading at 172.60. This means that the stock has a potential downside of -5.43%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 248.8 | 44.1% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 163.2 | -5.4% |